Omega Healthcare Investors, Inc. — FY2021 Form 10-K Summary
Business Context and Reporting Period
Omega is a healthcare real estate investment trust structured as an UPREIT. It owns and finances primarily skilled nursing and assisted living facilities through triple-net leases, mortgages, operator loans, and joint ventures in the United States and United Kingdom. The filing covers the fiscal year ended December 31, 2021; the source does not provide a separate Q4-only income statement.
- Portfolio: 960 facilities in 42 states and the U.K., operated by 63 third-party operators.
- Facility mix: 685 SNFs, 133 ALFs, 20 independent living facilities, 16 specialty facilities, two medical office buildings, 63 mortgaged facilities, and 41 facilities held for sale.
- Real estate investment assets totaled approximately $10.1 billion before accumulated depreciation; total assets were $9.64 billion.
Financial Performance and Key Metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenues | $1.063 billion | $892.4 million | 19.1% increase |
| Rental income | $923.7 million | $753.4 million | 22.6% increase |
| Mortgage interest income | $91.7 million | $89.4 million | 2.5% increase |
| Total expenses | $777.0 million | $734.9 million | 5.7% increase |
| Net income | $428.3 million | $163.5 million | 161.9% increase |
| Net income available to common stockholders | $416.7 million | $159.3 million | 161.6% increase |
| Diluted EPS | $1.75 | $0.70 | Increase |
| Nareit FFO | $655.2 million | $555.9 million | 17.9% increase |
| Cash flow from operations | $722.1 million | $708.3 million | 2.0% increase |
- Reported net margin was approximately 40.3%, but results were significantly affected by a $161.6 million gain on asset sales and other unusual items.
- Nareit FFO represented approximately $2.68 per diluted share based on the reported FFO and diluted share count; investors should verify the company’s officially reported per-share FFO measure.
- Real estate depreciation and amortization was $342.0 million. Provision for credit losses increased to $77.7 million from $38.0 million.
- Real estate impairments were $44.7 million, compared with $72.5 million in 2020.
- Interest expense increased to $234.6 million from $223.4 million.
Balance Sheet, Debt, Liquidity and Dividends
- Total equity was $4.11 billion and total net debt was approximately $5.3 billion, equal to approximately 56.4% of total capitalization.
- Debt had a weighted-average annual interest rate of 4.13%. Management stated that 100% of debt with outstanding principal balances had fixed interest payments after considering hedges.
- Debt included approximately $4.9 billion of senior unsecured notes, $362.1 million of secured borrowings, and a $1.45 billion revolving credit facility with no borrowings outstanding at year-end.
- Cash, cash equivalents, and restricted cash declined to $24.4 million from $167.6 million at December 31, 2020.
- Management stated that operating cash flow, asset sales, financing capacity, and equity programs were expected to fund needs for the next twelve months.
- Material cash requirements included $5.31 billion of debt principal, $1.42 billion of estimated long-term debt interest, $244.7 million of remaining construction and capital commitments, and $50.1 million of potential other-investment loan advances.
- Omega paid $637.6 million of common dividends during 2021. The quarterly dividend was $0.67 per share, and the board declared another $0.67 per-share dividend for the quarter ended December 31, 2021.
Material Changes Versus 2020
- Omega acquired 32 facilities for $604.0 million, including 24 facilities acquired from Healthpeak for $511.3 million, and invested $140.0 million in construction and capital improvements.
- Omega sold 48 facilities for $318.5 million of net proceeds and recognized a $161.6 million net gain. Assets held for sale increased to 41 facilities valued at $261.2 million from 22 facilities valued at $81.5 million.
- The company issued $700 million of 3.25% senior notes due 2033, redeemed $350 million of 4.375% notes due 2023, replaced its revolving credit facility with a new $1.45 billion facility, and replaced its prior $50 million term loan.
- Omega issued 7.6 million common shares through its ATM and dividend reinvestment programs for $278.4 million of net proceeds. No shares were repurchased during 2021.
- Credit-loss allowances increased to $144.5 million from $67.8 million, primarily reflecting operator distress and collateral revaluations.
- Six operators were placed on cash-basis revenue recognition in 2021. Omega wrote off approximately $36.0 million of straight-line rent receivables and lease inducements and recorded $83.4 million of impairments on loans to Agemo, Gulf Coast, and Guardian.
Outlook, Risks, Contingencies and Unusual Items
- Management expects near-term uncertainty to persist because of COVID-19 variants, staffing shortages, vaccine mandates, elevated labor and PPE costs, lower occupancy, repayment of government-assisted Medicare advances, and deferred payroll taxes.
- As of January 26, 2022, operators reported COVID-19 cases at 713 of 944 operating facilities, although Omega cautioned that it had not independently validated the information.
- Gulf Coast filed for Chapter 11 bankruptcy. Omega funded $20.5 million of debtor-in-possession financing and fully reserved the principal. Omega also agreed to sell 22 Gulf Coast facilities for estimated gross proceeds of $317.5 million, subject to closing conditions and a potential $18.7 million earnout.
- Guardian failed to make rent and mortgage payments. Omega reserved $38.2 million against its mortgage in the fourth quarter and continued restructuring discussions after year-end.
- In January and February 2022, another operator representing 3.4% of 2021 revenue failed to pay contractual rent and requested a short-term deferral.
- Government reimbursement, particularly Medicare and Medicaid, remains a key risk. CMS projected a 1.2% aggregate increase in fiscal 2022 SNF Medicare Part A payments, before potential value-based purchasing reductions.
- Other principal risks include operator bankruptcies, lease rejection, re-leasing and asset-sale execution, debt refinancing, interest rates and LIBOR transition, REIT qualification, regulatory enforcement, litigation, geographic and operator concentration, and U.K. currency and regulatory exposure.
- Pending matters include a securities class action and related derivative litigation, a DOJ investigation concerning Lakeway Hospital, and litigation involving the offset of Gulf Coast rent against subordinated debt. The filing does not provide a clear quantified loss estimate for these matters.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls.
Most Important Facts for Investors to Verify
- Whether operator occupancy, staffing, reimbursement, and rent collections recover from pandemic-related pressure.
- The ultimate recoveries, restructuring terms, and asset-sale proceeds related to Gulf Coast, Guardian, Agemo, and other cash-basis operators.
- Whether the $144.5 million credit-loss allowance and $261.2 million of assets held for sale adequately reflect current collateral values.
- Debt maturities beginning with $350 million of notes due in 2023 and the company’s ability to refinance without increasing borrowing costs or reducing dividends.
- The sustainability of the $0.67 quarterly dividend relative to recurring cash flow and FFO, excluding asset-sale gains and other nonrecurring items.
- The outcome of the securities litigation, Lakeway DOJ investigation, and Gulf Coast subordinated-debt offset litigation.
- The corrected 2021 dividend tax characterization: 4.3802% return of capital and 21.4776% capital gain, as stated in the filing.